BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kong FC, Zhang JQ, Zeng C, Chen WL, Ren WX, Yan GX, Wang HX, Li QB, Chen ZC. Inhibitory effects of parthenolide on the activity of NF-κB in multiple myeloma via targeting TRAF6. J Huazhong Univ Sci Technolog Med Sci 2015;35:343-9. [PMID: 26072071 DOI: 10.1007/s11596-015-1435-0] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
Number Citing Articles
1 Tian B, Xiao Y, Ma J, Ou W, Wang H, Wu J, Tang J, Zhang B, Liao X, Yang D, Wu Z, Li X, Zhou Y, Su M, Wang W. Parthenolide Inhibits Angiogenesis in Esophageal Squamous Cell Carcinoma Through Suppression of VEGF. Onco Targets Ther 2020;13:7447-58. [PMID: 32801767 DOI: 10.2147/OTT.S256291] [Reference Citation Analysis]
2 Kaushik D, Bhandari R, Kuhad A. TLR4 as a therapeutic target for respiratory and neurological complications of SARS-CoV-2. Expert Opin Ther Targets 2021;25:491-508. [PMID: 33857397 DOI: 10.1080/14728222.2021.1918103] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
3 Freund RRA, Gobrecht P, Fischer D, Arndt H. Advances in chemistry and bioactivity of parthenolide. Nat Prod Rep 2020;37:541-65. [DOI: 10.1039/c9np00049f] [Cited by in Crossref: 24] [Cited by in F6Publishing: 10] [Article Influence: 12.0] [Reference Citation Analysis]
4 Zhang Z, Zhao J, Pang Q, Wang A, Chen M, Wei X. An in vitro study on the effects of the combination of salinomycin with cisplatin on human gastric cancer cells. Mol Med Rep 2017;16:1031-8. [PMID: 28627601 DOI: 10.3892/mmr.2017.6731] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
5 Li X, Kong L, Yang Q, Duan A, Ju X, Cai B, Chen L, An T, Li Y. Parthenolide inhibits ubiquitin-specific peptidase 7 (USP7), Wnt signaling, and colorectal cancer cell growth. J Biol Chem 2020;295:3576-89. [PMID: 32029476 DOI: 10.1074/jbc.RA119.011396] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
6 Sun Y, Ye DW, Zhang P, Wu YX, Wang BY, Peng G, Yu SY. Anti-rheumatic drug iguratimod (T-614) alleviates cancer-induced bone destruction via down-regulating interleukin-6 production in a nuclear factor-κB-dependent manner. J Huazhong Univ Sci Technolog Med Sci 2016;36:691-9. [PMID: 27752889 DOI: 10.1007/s11596-016-1646-z] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
7 Guamán-Ortiz LM, Orellana MI, Ratovitski EA. Natural Compounds As Modulators of Non-apoptotic Cell Death in Cancer Cells. Curr Genomics 2017;18:132-55. [PMID: 28367073 DOI: 10.2174/1389202917666160803150639] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 4.0] [Reference Citation Analysis]
8 Seca AM, Silva AM, Pinto DC. Parthenolide and Parthenolide-Like Sesquiterpene Lactones as Multiple Targets Drugs. Elsevier; 2017. pp. 337-72. [DOI: 10.1016/b978-0-444-63931-8.00009-6] [Cited by in Crossref: 5] [Article Influence: 1.0] [Reference Citation Analysis]
9 Zhang Z, Zhao J, Mi Z, Pang Q, Wang A, Chen M, Liu X, Wei X, Liu T. Effects of salinomycin and 17‑AAG on proliferation of human gastric cancer cells in vitro. Mol Med Rep 2017;16:1063-70. [PMID: 28627587 DOI: 10.3892/mmr.2017.6735] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
10 Kouhpaikar H, Sadeghian MH, Rafatpanah H, Kazemi M, Iranshahi M, Delbari Z, Khodadadi F, Ayatollahi H, Rassouli FB. Synergy between parthenolide and arsenic trioxide in adult T-cell leukemia/lymphoma cells in vitro. Iran J Basic Med Sci 2020;23:616-22. [PMID: 32742599 DOI: 10.22038/ijbms.2020.40650.9610] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
11 Kuzmich NN, Sivak KV, Chubarev VN, Porozov YB, Savateeva-Lyubimova TN, Peri F. TLR4 Signaling Pathway Modulators as Potential Therapeutics in Inflammation and Sepsis. Vaccines (Basel) 2017;5:E34. [PMID: 28976923 DOI: 10.3390/vaccines5040034] [Cited by in Crossref: 161] [Cited by in F6Publishing: 160] [Article Influence: 32.2] [Reference Citation Analysis]